Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Each cell in our body experiences up to tens of thousands of DNA-damaging events per day, primarily from routine cellular ...

When president-elect Donald Trump announced that he would nominate Robert F Kennedy Jr to be his secretary of Health and ...

The country's public health could soon be overseen by someone who has a history of expressing beliefs in chemtrails, ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

On Friday, Hankison’s attorneys filed several motions, including requesting a new trial, in part, because prosecutors misled ...

Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Sarah Burris is a long-time veteran of political campaigns, having worked as a fundraiser and media director across the ...

Although FEBH premium prices are up significantly on average, there are plans with lower options this year too, offers the Consumers’ Checkbook benefits expert.